GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Regeneron Pharmaceuticals, Inc. (REGN) [hlAlert]

Rating:
Buy REGN
up 1,814.59 %

Regeneron Pharmaceuticals, Inc. (REGN) rated Buy with price target $120 by Brean Murray

Posted on: Monday,  Feb 13, 2012  12:25 PM ET by Brean Murray

Brean Murray rated Buy Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on 02/13/2012. Previously Brean Murray rated Buy Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on
10/08/2010., when the stock price was $28.10. Since then, Regeneron Pharmaceuticals, Inc. has gained 1814.59% as of 01/27/2016's recent price of $538.00.
If you would have followed the previous Brean Murray's recommendation on REGN, you would have gained 1814.59% of your investment in 1937 days.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients. Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion. Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage. Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients. Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/13/2012 12:25 PM Buy
None
116.13 120.00
as of 12/31/2012
1 Week down  -1.13 %
1 Month down  -3.10 %
3 Months up  12.05 %
1 YTD up  208.62 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/5/2011 10:25 AM Buy
None
55.55 67.00
4/28/2011 8:25 AM Buy
None
65.53 78.00
4/27/2011 8:25 AM Buy
None
55.34 67.00
4/18/2011 9:25 AM Buy
None
46.53 57.00
10/8/2010 9:25 AM Buy
None
28.10 38.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy